Rapport Therapeutics Unveils Positive Phase 2a RAP-219 Data for Focal Onset Seizures
Reuters
Nov 25, 2025
Rapport <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Positive Phase 2a RAP-219 Data for Focal Onset Seizures
Rapport Therapeutics Inc., a clinical-stage biotechnology company, announced that it will present new data from its Phase 2a trial of RAP-219 in focal onset seizures at the upcoming 2025 American Epilepsy Society $(AES)$ Annual Meeting, scheduled for December 5-9, 2025, in Atlanta. The presentations will include analyses of RAP-219's effect during the first month of treatment, consistency of efficacy over the treatment period, effectiveness across varying baseline disease severities, and impact on seizure severity. Both topline efficacy and safety data, as well as additional exploratory analyses, will be shared during poster sessions and a dedicated Scientific Exhibit Room at the meeting. The results have not yet been presented and will be made available during the AES conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591901-en) on November 25, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.